Prolia 60mg Injection

Osteoporosis/Bone disease

The human body reacts differently to Prolia 60mg Injection. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Prolia 60mg Injection are mentioned below: Rash, Sciatica, Musculoskeletal (bone, muscle, or joint ) pain. Infection in the upper respiratory tract, hair loss, headache, nerve pain, constipation, Eczema, urinary tract infection, Hypercholesterolemia (high cholesterol), Cystitis

The Prolia 60mg injection is injected in your upper thigh, stomach, or upper arm. Normally, you get it every 6 months. If cancer has spread to the bone, it is given every 4 weeks. If the cancer becomes a big bone tumor, you get it every 7 days. For more information, talk to your doctor. This injection should not be self-administered and should be given by a health care professional. Take a dose of Prolia 60mg injection every day at the same time and in the amount recommended by the doctor to get maximum benefit from the medicine. To make it more effective, take a balanced diet and take an adequate amount of vitamins and minerals while on treatment with Prolia 60mg injection

Prolia 60mg injection is a monoclonal antibody. It prevents bones from getting fractures or reduces the risk of bone loss by binding to a protein that weakens the bone. As a result, bones get strengthened and the risk of fractures is minimized.

It is advisable not to miss any dose. In case you miss a dose of Prolia 60mg Injection consult your doctor soon.

Missing the dose will impact the overall health of the patients. So, it is always advisable to follow the prescription of the doctor strictly.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Green W. (2024). Denosumab (Prolia) Injection: A New Approach to the Treatment of Women With Postmenopausal Osteoporosis. P T, 35(10):553–9.

Aubin JE, Bonnelye E. (2025). Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 11:905–913.

Sattler A, Schoppet M, et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 74:103–106. 

 Nicolopoulos K, Moshi MR, Stringer D, Ma N, Jenal M, Vreugdenburg T. (2025). The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. Arch Osteoporos. 10;18(1):18.

Jamshidi, A., Vojdanian, M., Soroush, M. et al.  (2025). Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther 24, 161. 

Francisco A. (2024). Sylvester, Effects of Digestive Diseases on Bone Metabolism. Pediatric Gastrointestinal and Liver Disease, (1116-1125.e8).

 Savelli,G.,Oliviero,S.,Viceconti,M.,Mattina,M,L,A., (2025). In silico prediction of hip fractures: improved fall modeling and expanded validation across cohorts with diverse risk profiles, Journal of the Mechanical Behavior of Biomedical Materials, 172, (107182).

Singh, Inderjeet; Jose, Vinu; Patel, Ronak; Arora, Sumit INTP23. (2025). Study 051-14 Investigator Team. Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. Indian Journal of Pharmacology 53(1):p 6-12.